Agranulocytosis and neutropenia in patients treated with antipsychotic drugs with focus on clozapine;Agranulozytose und leukopenie unter psychopharmaka mit schwerpunkt clozapin: Daten aus der arbeitsgemeinschaft arzneimitteltherapie bei psychischen erkrankungen - AGATE

Psychopharmakotherapie

Volumn 15, Issue 3, 2008, Pages 126-130

  Fuchs, Walter S ^a   Seifert, Roland ^a   Schneider, Erich ^a   Schnell, David ^a   Haen, Ekkehard ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Agranulocytosis; Antipsychotic drugs; Clozapine; Neutropenia

Indexed keywords

BIPERIDEN; CARBAMAZEPINE; CLOZAPINE; DIBENZEPIN; FLUPENTIXOL; FLUPENTIXOL DECANOATE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERAZINE; PIMOZIDE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; TRIMIPRAMINE; VALPROIC ACID; ZOTEPINE;

AGRANULOCYTOSIS; ARTICLE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA;

EID: 47949127050     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Atkin K, Kendall F, Gould D, Freemann H, et al. The incidence of neutropenia and agranulocytosis in patients treated with clozapine in the UK and Ireland Br J Psychiatry 1996;169:483-8.
2. Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Austral New Zealand J Psychiatry 1998;32:567-74.
3. Berliner N, Horwitz M, Loughran TP. Congenital and acquired neutropenia. Hematology 2004:63-79.
4. FDA Safety Information and Adverse Event Reporting: Clozaril (clozapine) tablets: revision to WBC monitoring schedule and other safety labelling, 2006.
5. Guest I, Sokoluk B, MacCrimmon J, Uetrecht J. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998;131:53-65.
6. Härtter S, Hiemke C. Wichtig bei atypischen Antipsychotika: Pharmakokinetik, Interaktionspotential und TDM. Pharmazie in unserer Zeit 2002;6:546-57.
7. Hough LB. Genomics meets histamine receptors: New subtypes, new receptors. Mol Pharmacol 2001;59:415-9.
8. Iverson S, Zahid N, Uetrecht JP. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chemico-Biological Interactions 2002;142:175-99.
9. Jann MW, Grimsley SR, Gray EC, Chang WH Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
10. Müller N, Riedel M, Möller HJ. Atypische Neuroleptika: Wirkstoffe gegen Wahn und Rückzug. Pharm Ztg 2000;43:3583-8.
11. Müller N, Riedel M. Therapie mit atypischen Neuroleptika. Pharmazie in unserer Zeit 2002;6:558-65.
12. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias. What is new? J Int Med 2001;250:476-91.
13. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000;58:207-16.